TY - JOUR
T1 - Sleep apnoea and visceral adiposity in middle-aged male and female subjects
AU - Kritikou, Ilia
AU - Basta, Maria
AU - Tappouni, Rafel
AU - Pejovic, Slobodanha
AU - Fernandez-Mendoza, Julio
AU - Nazir, Racha
AU - Shaffer, Michelle L.
AU - Liao, Duanping
AU - Bixler, Edward O.
AU - Chrousos, George P.
AU - Vgontzas, Alexandros N.
PY - 2013/3/1
Y1 - 2013/3/1
N2 - In obese male subjects, visceral adiposity has been associated with obstructive sleep apnoea (OSA), while studies in overweight males and females are limited. Our goal was to examine the association between OSA and visceral fat in a relatively nonobese population and assess the effects of 2 months placebo-controlled continuous positive airway pressure (CPAP) use on abdominal fat. 81 subjects, 22 middle-aged males and 20 post-menopausal females with OSA, and 19 male and 20 female controls were studied in the sleep laboratory for four nights. Abdominal (visceral (VAT) and subcutaneous (SAT) adipose tissue) and liver fat were assessed with computed tomography. OSA patients were re-assessed post-CPAP and post sham-CPAP. Apnoeic males had significantly higher VAT than controls, while apnoeic females had higher SAT than controls. In both sexes, OSA was associated with increased liver fat. In males, apnoea was associated with VAT whereas in females it was associated with subcutaneous, visceral and total fat. CPAP did not affect abdominal and liver fat. In overweight males, visceral adiposity is associated with OSA whereas in females it is associated with global adiposity. In overweight males, our therapeutic goal should be the reduction of visceral adiposity and its metabolic correlates, whereas, in females, weight loss may be sufficient. Shortterm CPAP treatment does not affect general, abdominal or intra-hepatic adiposity.
AB - In obese male subjects, visceral adiposity has been associated with obstructive sleep apnoea (OSA), while studies in overweight males and females are limited. Our goal was to examine the association between OSA and visceral fat in a relatively nonobese population and assess the effects of 2 months placebo-controlled continuous positive airway pressure (CPAP) use on abdominal fat. 81 subjects, 22 middle-aged males and 20 post-menopausal females with OSA, and 19 male and 20 female controls were studied in the sleep laboratory for four nights. Abdominal (visceral (VAT) and subcutaneous (SAT) adipose tissue) and liver fat were assessed with computed tomography. OSA patients were re-assessed post-CPAP and post sham-CPAP. Apnoeic males had significantly higher VAT than controls, while apnoeic females had higher SAT than controls. In both sexes, OSA was associated with increased liver fat. In males, apnoea was associated with VAT whereas in females it was associated with subcutaneous, visceral and total fat. CPAP did not affect abdominal and liver fat. In overweight males, visceral adiposity is associated with OSA whereas in females it is associated with global adiposity. In overweight males, our therapeutic goal should be the reduction of visceral adiposity and its metabolic correlates, whereas, in females, weight loss may be sufficient. Shortterm CPAP treatment does not affect general, abdominal or intra-hepatic adiposity.
UR - http://www.scopus.com/inward/record.url?scp=84875264700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875264700&partnerID=8YFLogxK
U2 - 10.1183/09031936.00183411
DO - 10.1183/09031936.00183411
M3 - Article
C2 - 22743670
AN - SCOPUS:84875264700
SN - 0903-1936
VL - 41
SP - 601
EP - 609
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 3
ER -